Home Page
Home Page
20:51:07 EDT Wed 16 Apr 2014
Enter Symbol
or Name
USA
Canada
QUALCOMM INC
Symbol U : QCOM
Recent Sedar Documents

News Buzz: QUALCOMM, Johnson & Johnson, Vale SA

2013-03-05 13:31 ET - News Release

NEW YORK, March 05, 2013 - vb-news.net, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on QUALCOMM, Johnson & Johnson, Vale SA.
QUALCOMM, Inc.(NASDAQ:QCOM) investors are a happy lot this morning. Their company has announced a sharp hike in dividend and a new multi-billion dollar share repurchase program.
The mobile chip company has announced that its Board of Directors has approved a 40 percent increase in the quarterly cash dividend and a new $5.0 billion stock repurchase program that replaces the $4.0 billion stock repurchase program.
Will QCOM Move Back To New highs On Solid News? Let’s Find Out Here http://vbtrendreport.com/aw/?code=QCOM
The dividend will increase to $0.35 per share from $0.25, or $1.40 per share annually. Dr. Paul E. Jacobs, chairman and CEO of Qualcomm said:"In recognition of our strong financial position and continued growth in our business, we are pleased to increase our quarterly cash dividend to a record 35 cents per share and to introduce a new $5.0 billion stock repurchase program. Our business model continues to generate strong operating cash flows that enable us to invest in and execute on our strategic priorities, while also returning capital to stockholders. Since these programs began in 2003, we have returned $19.9 billion to stockholders through a combination of stock repurchases and cash dividends."
Shares of Qualcomm are changing hands at $68, up 2 percent from yesterday’s close.
Meanwhile, Johnson & Johnson(NYSE:JNJ)’s Janssen Research & Development LLC has said that the U.S. Food and Drug Administration has rejected once again the approval of its blood thinner Xarelto for patients with acute coronary syndrome. The FDA had previously rejected Xarelto for this use in June expressing concerns about life-threatening bleeding.
Is JNJ a Buy At 52-week High? Grab Your Free Research Report Here http://vbtrendreport.com/aw/?code=JNJ
Janssen is evaluating the second letter and will respond to the agency's questions. It says that there was “no increase in fatal bleeding”, but is willing to work with the FDA on the issue.
Bayer is confident of Xarelto’s safety. At Monday’s close, shares of J&J and Bayer were trading at $77.20 and $99.06 respectively. Both stocks were inactive before the bell.
Moving from FMCG to mining. Yesterday, Vale SA (ADR)(NYSE:VALE) announced its results. It hadposted a loss of 51 cents a share, partly due to $5.66 billion in some asset-related charges. Not that the results excluding the write downs were impressive. The company still failed to meet analysts’ expectations. It made only 38 cents a share against Nomura’s estimate of 47 cents.Despite this, the stock moved higher yesterday. Here’s why- Most write-downs are factored in before the results and investors are more interested in the future- Vale’s project pipeline and value creation beyond 2013, and a better cost structure.
Has VALE Rebounded And Ready To Hit $20 This Month? Get Free Trend Analysis Here http://vbtrendreport.com/aw/?code=VALE
Woodworth and Ho of Nomura have raised their 2013 earnings forecast for Vale to $2.15 a share, from $1.90. They expect the company to make the most of higher iron ore prices which the stock price doesn’t reflect currently.About vb-news.net
vb-news.net’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
Disclaimer
The assembled information disseminated by vb-news.net is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. vb-news.net does expect that investors will buy and sell securities based on information assembled and presented in vb-news.net. PLEASE always do your own due diligence, and consult your financial advisor.
Contacts:vb-news.net 1419 Westwood Blvd Los Angeles, CA90024-4911staff@vb-news.netwww.vb-news.net

© 2014 Canjex Publishing Ltd. All rights reserved.